Technology & Pipeline

We are currently developing our antibiotic product candidate, OG253 as well as other homolog antibiotic product candidates, researching LBPs, and have other product candidates, including SMaRT Replacement Therapy positioned for outlicensing or partnering.

Technology Candidate Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
Lantibiotics OG253 C.difficile
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started
Live Biotherapeutics AG013 Oral mucositis
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

Lantibiotics

Lantibiotics are a class of antibiotics with a novel mechanism of action active against several multi-drug resistant organisms.

View Lantibiotics »

LBP

Our strategy is to develop genetically engineered safe bacterial strains designed to produce, deliver and release therapeutics locally at oral disease sites to prevent or cure a disease.

View LBP »